Alethio Therapeutics

Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers.

Its pipeline targets the mutant stem and progenitor cells that drive disease progression and fibrosis, with the aim of modifying rather than merely controlling disease course.

Target identification and validation is conducted using the company's ARTEMIS discovery engine, which integrates single-cell multi-omics, a large patient-derived tissue repository, and bone marrow organoid models.